Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain
Go back to Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain| (NASDAQ: OCUL) | Delayed: 9.97 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.97 | 52 Week High | $14.50 | |||
| Open | $9.97 | 52 Week Low | $4.04 | |||
| Day High | $9.97 | P/E | N/A | |||
| Day Low | $9.97 | EPS | $0.00 | |||
| Volume | 5,311 | |||||
